+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 30 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating the frequency of Neuronal Ceroid Lipofusinosis Type 2 CLN2 in children aged 2 to 6 years who have nonspecific neurological symptoms such as idiopathic seizures, speech disorders, and motor dysfunctions. This multicenter, non-drug screening study focuses on children without hypoxic ischemic encephalopathy, head trauma, or developmental brain anomalies, aiming to better understand the demographic and clinical features of those with possible CLN2 disease. Children first undergo assessments including recording demographic and medical history, seizure frequency, cognitive and language development evaluations, physical exams assessing muscle strength, gait, and coordination, as well as neurological evaluations using EEG and MRI scans. Those showing specific signs like speech disorder with seizures, movement problems, particular EEG responses, or MRI findings will have blood samples taken to measure Tripeptidyl Peptidase 1 enzyme levels. If enzyme activity is low, genetic testing is performed to investigate CLN2 disease. Participants are involved for up to one year during which various clinical, neurological, and imaging evaluations are done. Blood samples are collected for enzyme and genetic analyses. The main outcome measured is the frequency of CLN2 disease in this group. The study tracks each childs symptoms, neurological findings, and imaging results to better identify and understand CLN2 in children with these symptoms.

Age: 2Years - 6YearsAll Genders
34 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.

Age: 18Years - 75YearsAll GendersPhase 3
272 locations
E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
P

Actively Recruiting

Researchers are evaluating etelcalcetide in children with secondary hyperparathyroidism SHPT who also have chronic kidney disease CKD and are receiving hemodialysis. SHPT is a serious condition that develops early in CKD and can cause bone and growth problems as well as increased cardiovascular risks in children on dialysis. This phase 3 trial aims to provide important safety and efficacy data for etelcalcetide in pediatric patients aged 28 days to under 18 years, addressing the limitations of current treatments like vitamin D sterols. Participants are randomly assigned in a 51 ratio to receive either etelcalcetide along with standard care or standard care alone. The standard care may include treatments such as vitamin D sterols, calcium supplements, or phosphate binders. The study involves multiple doses of etelcalcetide, with assessments conducted over weeks to monitor its effects on parathyroid hormone levels and mineral balance. During the study, participants will undergo regular evaluations including blood tests to measure intact parathyroid hormone, calcium, and phosphorus levels. Researchers will also monitor safety by tracking adverse events and changes in vital signs, growth, and development stages. The primary outcome focuses on the percentage of participants achieving a significant reduction in hormone levels over weeks 20 to 27. The trial includes careful monitoring throughout treatment and up to approximately 30 weeks after the last dose.

Age: 0Years - 18YearsAll GendersPhase 3
43 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how well artificial intelligence AI and machine learning models can predict difficult airways in adults undergoing bariatric surgery. The study focuses on comparing AIs ability to predict challenging intubation with traditional clinical scoring methods in obese patients, addressing an important safety concern during anesthesia. Participants will have preoperative airway assessments including the Upper Lip Bite Test, Mallampati score, Body Mass Index BMI, thyromental distance, and sternomental distance recorded. During surgery, the airway view is graded using the Cormack-Lehane classification via direct laryngoscopy. This observational study collects these measurements to analyze AIs diagnostic accuracy in predicting difficult intubations. During the study, participants will undergo standard preoperative assessments and intraoperative airway evaluation. Researchers will measure how accurately the AI model predicts difficult intubation, count the number of intubation attempts needed, and record if alternative airway management techniques are used. Participation involves routine clinical procedures before and during surgery, with all data collected to improve airway management in obese patients.

Age: 18Years - 65YearsAll Genders
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are exploring symptoms of sluggish cognitive tempo SCT, also called cognitive disengagement syndrome CDS, in adults diagnosed with Functional Neurological Symptom DisorderConversion Disorder FNSDCD. This observational case-control study compares SCTCDS symptoms between adults with FNSDCD and healthy controls, aiming to understand how these symptoms relate to clinical features. The study hypothesizes that adults with FNSDCD will have higher SCTCDS symptoms than those without psychiatric conditions. Participants include adults aged 18 to 65 years with FNSDCD diagnosed by standard criteria and matched healthy controls without psychiatric disorders. No treatments or interventions are given by the study. Both groups complete baseline assessments using validated rating scales Barkleys Adult Sluggish Cognitive Tempo Scale Turkish version, Somatoform Dissociation Questionnaire, and Adult ADHD Self-Report Scale, alongside sociodemographic and clinical data collection. During the study, participants complete questionnaires and rating scales at hospital admission. Researchers analyze differences and relationships between SCTCDS symptoms and clinical variables using statistical methods. The study requires a minimum of 24 participants in each group to ensure adequate power. Participation is limited to a single evaluation visit with no invasive or interventional procedures involved.

Age: 18Years - 65YearsAll Genders
2 locations
C

Actively Recruiting

Researchers are evaluating the effects of two different regional anesthesia techniques, the serratus posterior superior intercostal plane block SPSIPB and the serratus anterior plane block SAPB, in patients undergoing non-intubated uniportal video-assisted thoracoscopic surgery NI-UniVATS. This minimally invasive surgical method is notable for avoiding intubation, maintaining spontaneous breathing, and reducing complications and recovery time. The trial aims to compare the intraoperative anesthetic and analgesic effects of SPSIPB, a recently described block, with the more commonly used SAPB to determine if SPSIPB provides similar pain control and anesthesia requirements during surgery. The study is a prospective, randomized, double-blind trial including 70 patients aged 18 to 65 years with certain health criteria. Participants are randomly assigned to receive either the SPSIPB or SAPB under ultrasound guidance before NI-VATS. SPSIPB involves injecting a local anesthetic near the serratus posterior superior muscle, while SAPB targets the myofascial plane near the serratus anterior muscle. Both techniques use specific volumes and concentrations of anesthetic and are performed with patients positioned laterally. Patients are monitored closely during and after the blocks, including nebulized lidocaine administration in the SPSIPB group to suppress cough reflex. During the trial, researchers will track anesthetic and analgesic use during surgery, postoperative pain using a numerical rating scale, total analgesic consumption, time to first rescue analgesia, recovery scores, and any block-related complications. Pain and analgesic use are assessed at multiple times up to 24 hours after surgery. The trial runs from January to August 2026, with careful monitoring to evaluate the effectiveness and safety of each block method in this surgical setting.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are comparing the effects of two types of full can exercisesconcentric and eccentricon the supraspinatus muscle structure in people with partial rotator cuff tears. These tears commonly cause shoulder pain and limit movement. The study focuses on understanding how different muscle contractions during exercise influence muscle architecture and clinical outcomes, aiming to improve rehabilitation strategies for this condition. Participants are randomly assigned to either a concentric or eccentric full can exercise group. Both groups receive a standard physiotherapy program that includes therapeutic ultrasound, transcutaneous electrical nerve stimulation TENS, and shoulder rehabilitation exercises. The concentric group emphasizes the lifting phase of the exercise, while the eccentric group focuses on the lowering phase. These exercise sessions are conducted three times a week for six weeks, totaling 18 sessions. During the study, participants will be assessed at the start and end of the six-week intervention. Researchers will measure changes in the supraspinatus muscle pennation angle using ultrasound imaging as the primary outcome. Secondary measures include muscle fiber length, cross-sectional area, pain levels, shoulder range of motion, muscle strength, functional status, and fear of movement. The study uses blinded assessors and randomized group assignment to monitor safety and effectiveness over the treatment period.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location
O

Actively Recruiting

Healthy Volunteer

Researchers are studying adults diagnosed with Methamphetamine Use Disorder MUD and Methamphetamine-Induced Psychotic Disorder MP to compare electrocardiogram ECG results and assess whether psychosis linked to methamphetamine use increases heart risks. This observational study takes place during inpatient psychiatric treatment, focusing on heart electrical activity differences between those with and without psychosis related to methamphetamine use. Participants include adults aged 18 to 65 diagnosed with MUD or MP, as well as a healthy control group without psychiatric disorders. All participants undergo routine clinical care without additional interventions from the study. ECGs and blood tests are performed at hospital admission and after six weeks of treatment. The MP group also receives assessments for psychotic symptom severity and insight level using standard scales. During the study, participants provide sociodemographic and clinical information. ECGs are reviewed by a cardiologist to identify abnormalities, and psychiatric symptoms are measured in the MP group. The main measure is ECG changes at admission and after six weeks. Additional outcomes include blood counts and psychometric scores. The study aims to understand heart health risks related to methamphetamine use and psychosis by comparing participants over six weeks of inpatient care.

Age: 18Years - 65YearsMALE
1 location

1-10 of 30

1